Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07837271 | Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST | active not recruiting | — | 288 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00265798 | Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 9, 2026 |
| clinicaltrials |
| NCT04595747 | Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) | active not recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06087263 | Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. | active not recruiting | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04821895 | Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients(GIST) | active not recruiting | — | 50 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05489237 | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | active not recruiting | Phase 1 | 276 | IDRX, Inc., a wholly owned subsidiary of GSK, LLCINDUSTRY | 11 | Jul 2, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib(INTRIGUE) | active not recruiting | Phase 3 | 453 | Deciphera Pharmaceuticals, LLCINDUSTRY | 22 | Feb 5, 2026 | clinicaltrials |
| NCT05245968 | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | active not recruiting | Phase 1 | 78 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 5 | Jan 20, 2026 | clinicaltrials |
| NCT05734105 | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib(INSIGHT) | active not recruiting | Phase 3 | 54 | Deciphera Pharmaceuticals, LLCINDUSTRY | 15 | Dec 17, 2025 | clinicaltrials |
| NCT01991379 | MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | active not recruiting | Phase 1 / Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06208748 | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | active not recruiting | Phase 2 | 40 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials